Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NAM

Financiado

Cerrado

New Antimicrobials

Antibacterial resistance is spreading globally at an alarming rate and continues to increase. New potent antibacterial agents and therapies are therefore continually needed. In recent years, new antibacterial compounds have mainly... ver más

31/05/2012

UOULU

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

OULUN YLIOPISTO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 5 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2012-05-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

5 Participantes

UOULU

0.00€ | Lider

NOVOZYMES AS

N.D. | Participante

UNITS

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ENABLE European Gram Negative Antibacterial Engine 101M€ Cerrado

ENZYBIOTX Upgrading business potential of Enzybiotx 75K€ Cerrado

TEJAM Novel Antimicrobials from Endophytes of Northern Medicinal P... 174K€ Cerrado

PDC2021-121544-I00 DISEÑO DE UNA NUEVA CLASE DE ANTIMICROBIANOS CONTRA INFECCIO... 133K€ Cerrado

GNA NOW NOVEL GRAM NEGATIVE ANTIBIOTIC NOW 22M€ Cerrado

Líder del proyecto

OULUN YLIOPISTO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Antibacterial resistance is spreading globally at an alarming rate and continues to increase. New potent antibacterial agents and therapies are therefore continually needed. In recent years, new antibacterial compounds have mainly been additions to the existing classes of drugs and very few new structures have been developed. Pharmaceutical industry has little interest in developing novel structures due to high investment and low profit expectancy. The derivatives of existing drugs typically raise bacterial resistance much faster than completely new compounds. To overcome the chronic problem of antibiotic resistance, totally new compounds and approaches are required, involving collaboration of researchers from various sectors and disciplines, as well as high societal investments. The NAM project aims to confront these problems by intense collaboration between industry and academia. The project aims at i) discovery of totally new antibacterial compounds from one of the richest untapped natural sources, endophytes, ii) development of totally new approaches based on antimicrobial host defense peptides, iii) research on the mechanisms of action of antimicrobial compounds. Through these objectives novel anti-infective agents can potentially be applied to the battle against bacterial resistance. NAM is a highly multidisciplinary consortium, consisting of groups in biology, chemistry, biophysics, biochemistry, microbiology and biotechnology. It consists of two companies (one SME and a large biotech company), and three university research laboratories in four different countries within the EU.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores